Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma

NCT02689167 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.

NCT NCT02689167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma
Lead sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 2
Overall status
Unknown status
Start date
February 19, 2016
Completion date
February 29, 2024
Enrollment
226 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney neoplasms, metastatic renal cell cancer